Companies › Elevar Therapeutics
1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Lirafugratinib FGFR2 inhibitor | FGFR2 | Phase 2 | FGFR2 Gene Fusion/Rearrangement | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07359820 | Lirafugratinib | Phase 2 | FGFR2 Gene Fusion/Rearrangement | Oncology | Sep 2027 |
Tyra Biosciences TransThera Sciences (Nanjing) Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.